BACKGROUND: Enterococci are an important cause of healthcare-associated infections. We retrospectively analyzed risk factors and outcome of vancomycin-resistant enterococci (VRE) and vancomycin-sensitive enterococci (VSE) infections. METHODS: Seven hundred fifty-two patients who received hematopoietic stem cell transplants from 2004 through 2008 at the University of Minnesota were included. RESULTS: Ninety-three patients had enterococcal bloodstream infection (BSI) during the first year after transplant. Vancomycin resistance was observed in 66% and 31% of isolates in adults and children, respectively. Cumulative incidence of VRE and VSE bacteremia was 6.6% (95% confidence interval [CI], 4.8%-8.4%) and 5.7% (95% CI, 4.0%-7.4%), respectively. Colonization with VRE before or after transplant was a risk factor for VRE bacteremia (odds ratio [OR], 3.3 [95% CI, 1.3-8.3] and 7.0 [95% CI, 4.0-14.8], respectively). Delay in engraftment increased the incidence of VRE bacteremia from 4.5% (95% CI, 2.9-6.6) if engrafted before day 21 and to 15% (95% CI, 3.2%-38%) if engrafted between days 36 and 42. In adults, mortality 30 days after infection was 38% for both VRE (95% CI, 25%-54%) and VSE cases (95% CI, 21%-62%). The hazard ratio for all-cause mortality up to 1 year after transplant was 4.2 (95% CI, 3.1-6.9) and 2.7 (95% CI, 1.4-5.1) for patients with VRE and VSE BSIs, respectively, compared to patients without enterococcal BSI. In pediatric patients, mortality 30 days after VRE and VSE bacteremia was 20% (95% CI, 5.4%-59%) and 4.5% (95% CI, .6%-28%), respectively. CONCLUSION: High rates of vancomycin resistance and association of enterococcal infections with significant mortality warrant further efforts to optimize prevention and management of these infections.
BACKGROUND: Enterococci are an important cause of healthcare-associated infections. We retrospectively analyzed risk factors and outcome of vancomycin-resistant enterococci (VRE) and vancomycin-sensitive enterococci (VSE) infections. METHODS: Seven hundred fifty-two patients who received hematopoietic stem cell transplants from 2004 through 2008 at the University of Minnesota were included. RESULTS: Ninety-three patients had enterococcal bloodstream infection (BSI) during the first year after transplant. Vancomycin resistance was observed in 66% and 31% of isolates in adults and children, respectively. Cumulative incidence of VRE and VSE bacteremia was 6.6% (95% confidence interval [CI], 4.8%-8.4%) and 5.7% (95% CI, 4.0%-7.4%), respectively. Colonization with VRE before or after transplant was a risk factor for VRE bacteremia (odds ratio [OR], 3.3 [95% CI, 1.3-8.3] and 7.0 [95% CI, 4.0-14.8], respectively). Delay in engraftment increased the incidence of VRE bacteremia from 4.5% (95% CI, 2.9-6.6) if engrafted before day 21 and to 15% (95% CI, 3.2%-38%) if engrafted between days 36 and 42. In adults, mortality 30 days after infection was 38% for both VRE (95% CI, 25%-54%) and VSE cases (95% CI, 21%-62%). The hazard ratio for all-cause mortality up to 1 year after transplant was 4.2 (95% CI, 3.1-6.9) and 2.7 (95% CI, 1.4-5.1) for patients with VRE and VSE BSIs, respectively, compared to patients without enterococcal BSI. In pediatric patients, mortality 30 days after VRE and VSE bacteremia was 20% (95% CI, 5.4%-59%) and 4.5% (95% CI, .6%-28%), respectively. CONCLUSION: High rates of vancomycin resistance and association of enterococcal infections with significant mortality warrant further efforts to optimize prevention and management of these infections.
Authors: N G Almyroudis; A J Lesse; T Hahn; G Samonis; P A Hazamy; K Wongkittiroch; E S Wang; P L McCarthy; M Wetzler; B H Segal Journal: Infect Control Hosp Epidemiol Date: 2011-05 Impact factor: 3.254
Authors: I Chatterjee; J M Dulhunty; J Iredell; J E Gallagher; A Sud; M Woods; J Lipman Journal: Anaesth Intensive Care Date: 2009-11 Impact factor: 1.669
Authors: W Charles Huskins; Charmaine M Huckabee; Naomi P O'Grady; Patrick Murray; Heather Kopetskie; Louise Zimmer; Mary Ellen Walker; Ronda L Sinkowitz-Cochran; John A Jernigan; Matthew Samore; Dennis Wallace; Donald A Goldmann Journal: N Engl J Med Date: 2011-04-14 Impact factor: 91.245
Authors: Mini Kamboj; Dick Chung; Susan K Seo; Eric G Pamer; Kent A Sepkowitz; Ann A Jakubowski; Genovefa Papanicolaou Journal: Biol Blood Marrow Transplant Date: 2010-05-26 Impact factor: 5.742
Authors: Martin Wolkewitz; Ralf Peter Vonberg; Hajo Grundmann; Jan Beyersmann; Petra Gastmeier; Sina Bärwolff; Christine Geffers; Michael Behnke; Henning Rüden; Martin Schumacher Journal: Crit Care Date: 2008-04-02 Impact factor: 9.097
Authors: Armin Rashidi; Maryam Ebadi; Robin R Shields-Cutler; Todd E DeFor; Gabriel A Al-Ghalith; Patricia Ferrieri; Jo-Anne H Young; Gary M Dunny; Dan Knights; Daniel J Weisdorf Journal: Biol Blood Marrow Transplant Date: 2018-01-31 Impact factor: 5.742
Authors: Maria J G T Vehreschild; Miriam Haverkamp; Lena M Biehl; Sebastian Lemmen; Gerd Fätkenheuer Journal: Infection Date: 2018-09-03 Impact factor: 3.553
Authors: Mini Kamboj; Nina Cohen; Yao-Ting Huang; Marina Kerpelev; Ann Jakubowski; Kent A Sepkowitz; Genovefa A Papanicolaou; Susan K Seo Journal: Biol Blood Marrow Transplant Date: 2018-11-15 Impact factor: 5.742
Authors: Michael J Satlin; Rosemary Soave; Alexandra C Racanelli; Tsiporah B Shore; Koen van Besien; Stephen G Jenkins; Thomas J Walsh Journal: Leuk Lymphoma Date: 2014-03-24
Authors: Susan K Seo; Kun Xiao; Yao-Ting Huang; Ubonvan Jongwutiwes; Dick Chung; Molly Maloy; Sergio Giralt; Juliet N Barker; Ann A Jakubowski; Genovefa A Papanicolaou Journal: J Infect Date: 2014-06-12 Impact factor: 6.072